SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indevus Pharmaceuticals (NasdaqNM:IDEV)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: SemiBull who wrote (2)9/30/2003 8:03:45 PM
From: SemiBull  Read Replies (1) of 78
 
4:11PM Indevus Pharma announces publication of positive Phase II results (IDEV) 5.35 unch: Co announces that the publication of data by the Journal of the American Medical Assoc (JAMA) showing that a novel synthetic anti-inflammatory and analgesic cannabinoid compound known as IP 751 (also as CT-3) significantly reduced the degree of neuropathic pain in a Phase II clinical trial without causing psychoactive adverse events.
finance.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News